Chen and associates76 compared subcutaneous injections of ETA against non-biological DMARDs for 1 year and observed a greater BW gain, hyperuricemia prevalence, decreased fasting plasma glucose-dependent insulinotropic polypeptide (GIP) concentrations, and loss of post-oral glucose suppression of plasma leptin concentration in the ETA arm. The gene discussed is GIP; the disease is hyperuricemia.